 |
|
|
 |
|
Celebrex Plus Lipitor Could Fight Prostate Cancer
|
 |  |  |  | Related Healthscout Videos |  |
|
Page: << Prev | 1 | 2 This study aimed to delay the progression of androgen-dependent tumors to androgen-independent tumors, thus allowing doctors more time to administer anti-hormone therapy. Anti-androgen therapy is less toxic than many other cancer therapies, as are Lipitor and Celebrex.
"Comparing complications for many anti-cancer treatments, these drugs generally would be very safe," Ennis said. (Celebrex, a cox-2 inhibitor, is the only drug in this class still on the market in the United States; two others, Vioxx and Bextra, were withdrawn because of safety issues).
In the study, the investigators first cultured prostate tumors in mice, then added in either Lipitor or Celebrex, and then the combination of the two drugs.
Text Continues Below

All three approaches inhibited cancer growth. Interestingly, however, the combination of Lipitor and Celebrex at lower doses than when given individually resulted in a greater effect, the team found.
"It had a pretty substantial effect with this combination," said study senior author Allan Conney, director of the Susan Lehman Komen Laboratory for Cancer Research at the Ernest Mario School of Pharmacy of Rutgers University, in New Brunswick, N.J.
"We're hoping that this can be extrapolated to humans," Conney added. "There's a need to do a clinical trial on this combination of Lipitor and Celebrex to see if it can prolong the time that it takes to convert the androgen-dependent tumors to androgen-independent tumors, which are the more severe kind."
As of now, it's unclear why Lipitor and Celebrex are having this effect on prostate tumors.
Ennis doubted it was a cholesterol issue. "Statins as a group must have another effect beyond lowering cholesterol," he said. "They're known to have some anti-inflammatory effects but what they're doing to cancer isn't known yet. Once we figure that out, we may be able to develop better drugs that do the same thing."
"That's very exciting but not yet enough to start prescribing this for prostate cancer," Ennis added.
More information
There's more on prostate cancer at the American Cancer Society.
Page: << Prev | 1 | 2
|
Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/14/2008
|
 |

SOURCES: Allan Conney, Ph.D., Garbe professor, cancer and leukemia research, and director, Susan Lehman Komen Laboratory for Cancer Research, Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, N.J.; Ronald D. Ennis, M.D., director, radiation oncology, St. Luke's Roosevelt Hospital, Continuum Cancer Centers, New York City; K. Scott Coffield, M.D., professor, surgery, Texas A&M Health Science Center College of Medicine and urologist-oncologist, Scott&White
|